Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Kessel

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Nature Biotechnology|June 4, 2024
Author Correction: Why Japan lacks a vibrant biotech industryMark Kessel, Chris Vickrey
Nature Biotechnology|April 22, 2024
Why Japan lacks a vibrant biotech industryMark Kessel, Chris Vickrey
Nature Reviews. Drug Discovery|January 4, 2007
Avoiding premature licensingMark Kessel, Sam Hall
Nature Biotechnology|February 6, 2016
Preparing for crisesMark Kessel, Robert Masella
Nature Biotechnology|August 10, 2007
A better prescription for drug-development financingMark Kessel, Frederick Frank
The Lancet. Global Health|March 22, 2015
Diagnostics for hepatitis C: an urgent need for actionClaudia M Denkinger, Mark Kessel
Nature Biotechnology|August 10, 2013
Stock options and beyondJohn J Cannon, Mark Kessel
Nature Biotechnology|May 13, 2015
What Ebola tells us about outbreak diagnostic readinessMark D Perkins, Mark Kessel
Nature Biotechnology|March 3, 2019
How to fix tuberculosis R&D-the community speaksMark Kessel, Bhavana Rana, Catharina Boehme
Nature Biotechnology|April 8, 2016
Ignore the Delaware director-compensation cases at your perilDoreen Lilienfeld, Brian Polovoy, Mark Kessel
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Nature Biotechnology|June 4, 2024
Author Correction: Why Japan lacks a vibrant biotech industryMark Kessel, Chris Vickrey
Nature Biotechnology|April 22, 2024
Why Japan lacks a vibrant biotech industryMark Kessel, Chris Vickrey
Nature Reviews. Drug Discovery|January 4, 2007
Avoiding premature licensingMark Kessel, Sam Hall
Nature Biotechnology|February 6, 2016
Preparing for crisesMark Kessel, Robert Masella
Nature Biotechnology|August 10, 2007
A better prescription for drug-development financingMark Kessel, Frederick Frank
The Lancet. Global Health|March 22, 2015
Diagnostics for hepatitis C: an urgent need for actionClaudia M Denkinger, Mark Kessel
Nature Biotechnology|August 10, 2013
Stock options and beyondJohn J Cannon, Mark Kessel
Nature Biotechnology|May 13, 2015
What Ebola tells us about outbreak diagnostic readinessMark D Perkins, Mark Kessel
Nature Biotechnology|March 3, 2019
How to fix tuberculosis R&D-the community speaksMark Kessel, Bhavana Rana, Catharina Boehme
Nature Biotechnology|April 8, 2016
Ignore the Delaware director-compensation cases at your perilDoreen Lilienfeld, Brian Polovoy, Mark Kessel
Pageof 3